Oncotarget

Research Papers:

Heregulin-HER3-HER2 signaling promotes matrix metalloproteinase-dependent blood-brain-barrier transendothelial migration of human breast cancer cell lines

Majid Momeny _, Jodi M. Saunus, Flavia Marturana, Amy E. McCart Reed, Debra Black, Gianluca Sala, Stefano Iacobelli, Jane D. Holland, Dihua Yu, Leonard Da Silva, Peter T. Simpson, Kum Kum Khanna, Georgia Chenevix-Trench and Sunil R. Lakhani

PDF  |  HTML  |  Supplementary Files  |  How to cite  |  Order a Reprint

Oncotarget. 2015; 6:3932-3946. https://doi.org/10.18632/oncotarget.2846

Metrics: PDF 1726 views  |   HTML 2101 views  |   ?  


Abstract

Majid Momeny1, Jodi M. Saunus1,2, Flavia Marturana1, Amy E. McCart Reed1,2, Debra Black1,2, Gianluca Sala3, Stefano Iacobelli3, Jane D. Holland4, Dihua Yu5, Leonard Da Silva1,7, Peter T. Simpson1,2,7, Kum Kum Khanna2, Georgia Chenevix-Trench2, Sunil R. Lakhani1,6,7

1University of Queensland, UQ Center for Clinical Research, Herston, QLD, Australia

2QIMR Berghofer Medical Research Institute, Herston, QLD, Australia

3Mediapharma s.r.l., Chieti, Italy

4Department of Cancer Research, Max Delbruck Center for Molecular Medicine, Berlin, Germany

5Department of Molecular and Cellular Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA

6Pathology Queensland, The Royal Brisbane & Women’s Hospital, Herston, QLD Australia

7The University of Queensland School of Medicine, Herston, QLD Australia

Correspondence to:

Sunil R. Lakhani, e-mail: s.lakhani@uq.edu.au

Keywords: Heregulin, HER2, HER3, blood-brain-barrier, matrix metalloproteinase, breast cancer-brain metastases

Received: July 23, 2014     Accepted: December 05, 2014     Published: February 19, 2015

ABSTRACT

HER2-positive breast tumors are associated with a high risk of brain relapse. HER3 is thought to be an indispensible signaling substrate for HER2 (encoded by ERBB2) and is induced in breast cancer-brain metastases, though the molecular mechanisms by which this oncogenic dimer promotes the development of brain metastases are still elusive. We studied the effects of the HER3-HER2 ligand, heregulin (neuregulin-1, broadly expressed in the brain), on luminal breast cancer cell lines in vitro. Treatment of SKBr3 (ERBB2-amplified), MDA-MB-361 (ERBB2-amplified, metastatic brain tumor-derived) and MCF7 (HER2-positive, not ERBB2-amplified) cells with exogenous heregulin increased proliferation and adhesive potential, concomitant with induction of cyclin D1 and ICAM-1, and suppression of p27. All three cell lines invaded through matrigel toward a heregulin chemotactic signal in transwell experiments, associated with activation of extracellular cathepsin B and matrix metalloproteinase-9 (MMP-9). Moreover, heregulin induced breast cancer cell transmigration across a tight barrier of primary human brain microvascular endothelia. This was dependent on the activity of HER2, HER3 and MMPs, and was completely abrogated by combination HER2-HER3 blockade using Herceptin® and the humanized HER3 monoclonal antibody, EV20. Collectively these data suggest mechanisms by which the HER3-HER2 dimer promotes development of metastatic tumors in the heregulin-rich brain microenvironment.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 2846